Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 3546-41-6 Chemical Structure| 3546-41-6

Structure of Pyrvinium pamoate
CAS No.: 3546-41-6

Chemical Structure| 3546-41-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pyrvinium pamoate is used for the treatment of pinworm infection. It also can inhibit WNT pathway.

Synonyms: Pyrvinium embonate; Pyrvinium (pamoate); NSC 223622

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pyrvinium pamoate

CAS No. :3546-41-6
Formula : C75H70N6O6
M.W : 1151.39
SMILES Code : C[N+]1=C2C=CC(N(C)C)=CC2=CC=C1/C=C/C3=C(C)N(C4=CC=CC=C4)C(C)=C3.C[N+]5=C6C=CC(N(C)C)=CC6=CC=C5/C=C/C7=C(C)N(C8=CC=CC=C8)C(C)=C7.O=C(C9=C(O)C(CC%10=C%11C=CC=CC%11=CC(C([O-])=O)=C%10O)=C%12C=CC=CC%12=C9)[O-]
Synonyms :
Pyrvinium embonate; Pyrvinium (pamoate); NSC 223622
MDL No. :MFCD00010090
InChI Key :OOPDAHSJBRZRPH-UHFFFAOYSA-L
Pubchem ID :54680693

Safety of Pyrvinium pamoate

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302+H312+H332-H315-H319-H335-H350
Precautionary Statements:P261-P280-P305+P351+P338
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
CD4+ T cells 2 nM 1 hour To evaluate the effect of Pyrvinium pamoate on the metabolism of CD4+ T cells, results showed that PP significantly altered the metabolite levels of CD4+ T cells, including an increase in NADH and de novo purine synthesis metabolites, and a decrease in alpha-ketoglutarate (alpha-KG) and pyruvate levels. PMC10604707
Drug-sensitive and drug-resistant M. tb clinical isolates 0.1–10 μg/mL 15 days To evaluate the inhibitory effect of Pyrvinium pamoate on drug-sensitive and drug-resistant M. tb clinical isolates, results showed that PP could inhibit the growth of these strains. PMC7034053
Mycobacterium smegmatis 25 μM 2 days To screen for drugs that inhibit the growth of M. smegmatis, Pyrvinium pamoate showed significant inhibitory effects. PMC7034053
LASCPC-01 cells 100 nM 24 and 48 hours Pyrvinium pamoate (PP) demonstrated the most robust inhibitory effect among all candidates at the same concentration and duration of treatment, reducing the levels of MYCN, ELAVL3, RICTOR, and neuroendocrine markers while inducing cell apoptosis. PMC10684895
Mycobacterium tuberculosis H37Rv 0.1–10 μg/mL 30 days To evaluate the inhibitory effect of Pyrvinium pamoate on M. tb H37Rv, results showed that PP could inhibit the growth of M. tb H37Rv in a dose-dependent manner. PMC7034053
Jurkat T cells 5 nM 30 minutes To evaluate the effect of PP on the thermal stability of proteins in Jurkat T cells through PISA experiments, results showed that PP significantly destabilized the thermal stability of pyruvate dehydrogenase kinase 1 (PDK1). PMC10604707
U2OS/MTX300 cells 0-200 nM 48 hours Inhibited CBX4 protein levels, reduced cell migration and invasion PMC7048933
RAS-activated AML cells 10 μM 72 hours Pyrvinium pamoate showed significant cell growth inhibition in RAS-activated AML cells, particularly in trametinib-resistant PTPN11 or KRAS mutated samples. PMC9061298
NF1KO_1 and NF1KO_2 TF-1 cells 10 μM 72 hours Pyrvinium pamoate showed significant cell growth inhibition in NF1KO_1 and NF1KO_2 TF-1 cells. PMC9061298
FP-CSC clones (FP#1, FP#2, FP#6) 100 nM 72 hours To evaluate the inhibitory effect of PP on FP-CSC clones, the results showed that PP significantly inhibited mammosphere formation in FP-CSC clones. PMC8808379
FP#1, FP#2, FP#6 100 nM 72 hours To evaluate the effect of PP on the proliferation and cell death of FP#1, FP#2, FP#6 cells, the results showed that PP significantly increased cell death. PMC8808379
AW13516 0.5, 1, 2, 3 µM 72 hours Pyrvinium pamoate significantly reduced the transforming ability of cells expressing the fusion protein and inhibited the Wnt/β-catenin signaling pathway by degrading β-catenin. PMC10912599
AW8507 0.5, 1, 2, 3 µM 72 hours Pyrvinium pamoate significantly reduced the transforming ability of cells expressing the fusion protein and inhibited the Wnt/β-catenin signaling pathway by degrading β-catenin. PMC10912599
NT-8e 0.5, 1, 2, 3 µM 72 hours NT-8e cells showed higher sensitivity to pyrvinium pamoate compared to other HNSCC cells without the fusion, indicating the drug's specific inhibitory effect on fusion-expressing cells. PMC10912599
FP#1 and FP#6 100 nM To evaluate the effect of PP on the clonogenic ability of FP#1 and FP#6 cells in soft agar, the results showed that PP significantly inhibited colony formation. PMC8808379

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice orthotopic osteosarcoma metastasis model intraperitoneal (IP) delivery 0.5 mg/kg three times per week for two weeks Reduced lung metastasis of osteosarcoma PMC7048933
Mice TKO mouse model Intraperitoneal injection 0.2 mg/kg Every other day for four weeks PP treatment effectively suppressed tumor growth, reduced the [18F]-FDG PET/CT signal, prolonged the survival of mice, and decreased the tumor metastatic burden. PMC10684895
Mice NOD.Cg-Prkdcscid/J mice Oral gavage and intraperitoneal injection 0.25 mg/kg/d 5 days/week for 25 days The combination of pyrvinium pamoate and trametinib significantly inhibited the propagation of RAS+ AML cells in mice, indicating potential anti-leukemic activity. PMC9061298
NSG mice TNBC CSC model Intraperitoneal injection 0.3 mg/kg to 1.2 mg/kg Once daily for four weeks To evaluate the effect of PP on tumor growth and metastasis in the TNBC CSC model, the results showed that PP significantly inhibited tumor growth and reduced lung metastasis. PMC8808379
Mice NOD-SCID mice Oral 10 mg/kg every 48 hours for 9 days Pyrvinium pamoate significantly reduced tumor volume and improved the survival of mice bearing tumors of fusion-overexpressing cells. PMC10912599
C57BL/6 mice M. tb H37Rv infection model Intraperitoneal injection 0.5–1.5 mg/kg/day 5 days/week for 6 weeks To evaluate the therapeutic effect of Pyrvinium pamoate on M. tb H37Rv-infected mice, results showed that PP significantly reduced bacterial CFUs in lung, spleen, and liver tissues and effectively inhibited inflammatory responses. PMC7034053
Mice Experimental autoimmune encephalomyelitis (EAE) model Intraperitoneal injection 0.7 mg/kg Days 0,1,3,5,7,9,11 post MOG, lasting 11 days To evaluate the effect of PP on the EAE model, results showed that PP significantly prevented the onset of EAE and reduced the proliferation of CD4+ T cells and the production of inflammatory cytokines. PMC10604707

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.87mL

0.17mL

0.09mL

4.34mL

0.87mL

0.43mL

8.69mL

1.74mL

0.87mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories